Highlights: • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board. o Dr. Bill Richards is among the world’s… Read more
The Company is extremely pleased to announce that the Offer has now closed and has been heavily oversubscribed. The issue… Read more
Psychennex Pty Ltd Psychedelic-assisted psychotherapy offers the hope of sustained improvement to the significant proportion of people for whom traditional… Read more
Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a medicinal cannabinoid and psychedelic pharmaceutical development company, is… Read more
For a non-renounceable pro rata offer of 1 option to acquire a fully paid ordinary share in the Company (Loyalty… Read more
IHL-675A is a cannabinoid combination drug n animal models of: comprising hydroxychloroquine sulphate (‘HCQ’) and cannabidiol (‘CBD’). HCQ is a… Read more
IHL-675A is a combination cannabinoid drug comprising cannabidiol (‘CBD’) and hydroxychloroquine (‘HCQ’) in a fixed dose combination. IHL-675A was observed… Read more
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide… Read more
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical cannabinoid and psychedelic medicines company, is pleased… Read more